The Growing Burden of Tuberculosis
Global Trends and Interactions With the HIV Epidemic

Elizabeth L. Corbett, PhD; Catherine J. Watt, DPhil; Neff Walker, PhD; Dermot Maher, BM, BCh; Brian G. Williams, PhD; Mario C. Raviglione, MD; Christopher Dye, DPhil

Background: The increasing global burden of tuberculosis (TB) is linked to human immunodeficiency virus (HIV) infection.

Methods: We reviewed data from notifications of TB cases, cohort treatment outcomes, surveys of Mycobacterium tuberculosis infection, and HIV prevalence in patients with TB and other subgroups. Information was collated from published literature and databases held by the World Health Organization (WHO), the Joint United Nations Programme on HIV/ACquired Immunodeficiency Syndrome (UNAIDS), the US Census Bureau, and the US Centers for Disease Control and Prevention.

Results: There were an estimated 8.3 million (5th-95th centiles, 7.3-9.2 million) new TB cases in 2000 (137/100000 population; range, 121/100000-151/100000). Tuberculosis incidence rates were highest in the WHO African Region (290/100000 per year; range, 265/100000-331/100000), as was the annual rate of increase in the number of cases (6%). Nine percent (7%-12%) of all new TB cases in adults (aged 15-49 years) were attributable to HIV infection, but the proportion was much greater in the WHO African Region (31%) and some industrialized countries, notably the United States (26%). There were an estimated 1.8 million (5th-95th centiles, 1.6-2.2 million) deaths from TB, of which 12% (226000) were attributable to HIV. Tuberculosis was the cause of 11% of all adult AIDS deaths. The prevalence of M. tuberculosis–HIV coinfection in adults was 0.36% (11 million people). Coinfection prevalence rates equaled or exceeded 5% in 8 African countries. In South Africa alone there were 2 million coinfected adults.

Conclusions: The HIV pandemic presents a massive challenge to global TB control. The prevention of HIV and TB, the extension of WHO DOTS programs, and a focused effort to control HIV-related TB in areas of high HIV prevalence are matters of great urgency.
sons aged 15 through 49 years because of the insufficient and conflicting data regarding HIV-associated TB in children, 38 and because of the lack of HIV prevalence estimates in older adults. Our objectives were to develop and enumerate a range of indicators of the burden of HIV-related TB, thereby providing a firm basis for setting disease control targets, and for monitoring trends as well as the impact of interventions.

METHODS

The estimates are based on TB notification and treatment outcomes, on surveys of TB infection and disease, and on surveys of HIV prevalence in TB patients and other population groups (eg, pregnant women). Country-specific estimates of the prevalence of HIV infection among persons aged 15 through 49 years (hereafter referred to as adult HIV prevalence) were obtained from the Joint United Nations Programme on HIV/AIDS (UNAIDS). 39 Essential formulas are given in Figure 1.

ESTIMATES OF TB INCIDENCE

At the start of 2000 WHO published TB incidence estimates stratified by age group and smear status for 209 countries and territories.37 They consisted of previously published estimates38 updated using trends in notification rates.

HIV Prevalence in TB Patients Compared With General Populations

A literature and database search was conducted for data on HIV prevalence in patients with TB (I HIV/TB) that could be matched with adult HIV prevalence (N HIV/ N TB) in the same region and time period. Equation 7 in Figure 1 (derived from equation 6) relates these 2 sets of data to IRR, which can then be estimated by maximum likelihood of fit. Equation 6 makes it clear that IRR depends on both relative MTB infection rates (m HIV/ m TB) and rates of progression to active disease (r HIV/ r TB). Since relative MTB infection rates are likely to vary from country to country, as may progression rates, IRR is expected to vary, too.41 We attempted to identify regional IRR variations within limits set by the quality of data.

Figure 1. Formulas for estimating tuberculosis (TB) incidence, prevalence, and deaths.
 notified, but non-DOTS ones not necessarily so.39 Patients treated in the private sector, of whom many receive nonstandard drug regimens,44 are included among non-DOTS patients.

In our estimation of the proportion of HIV-positive and HIV-negative patients with TB who received TB treatment, the proportion of those who received TB treatment was taken to be independent of HIV status. This probably underestimated the proportion of HIV-associated TB patients who were left untreated in resource-poor settings.16-20,22-26

TB PREVALENCE AND HIV-ASSOCIATED TB TRANSMISSION

Estimates of TB prevalence were calculated from the product of incidence and the estimated duration of illness (equation 2), as previously described.34 The exception was China, where the prevalence rate of smear-positive TB was measured directly by a survey carried out in 2000. We assumed that duration of illness differed when patients were smear positive or smear negative, HIV infected or not, treated through DOTS or other programs, or untreated (Table 1).34

The point prevalence of active, smear-positive disease is closely correlated with current TB transmission.53,70

We used the HIV-infected proportion of prevalent smear-positive cases as a measure of the proportion of TB transmission events that were likely to be from HIV-positive patients. This assumes that the impact of HIV on TB infectivity is related to likelihood and duration of smear-positive disease, but that infectivity per unit of time is independent of HIV status.

TB DEATHS AND PROPORTION ATTRIBUTABLE TO HIV

The number of TB deaths is the product of incidence by the case fatality rate (CFR) (equation 4). Tuberculosis deaths include those of patients who die without ever being treated or while receiving treatment, as well as late deaths from relapse or posttuberculous complications.

A literature search was conducted for mortality during treatment; risk of TB relapse and late complications; and autopsy series for the cause of death in patients with TB according to HIV status, smear status, and regimen.47,48,56-69,71-84

These data, along with treatment results reported to WHO and revised country-specific estimates calculated for 1997,24 were used to estimate CFRs for patients with TB.34 In nonindustrialized countries the estimated CFRs for patients treated through DOTS are lower than for patients treated through other programs because the DOTS strategy promotes rapid diagnosis and rifampicin-based drug regimens. In industrialized countries, where standard regimens for TB contain rifampicin and there is ready access to high-quality care for HIV, including highly active antiretroviral therapy (HAART), CFRs for TB were assumed to be the same whatever or not treatment programs were formally classified as DOTS.53-61

HIV-Negative TB Patients

For smear-positive HIV-negative patients in nonindustrialized countries, estimated lifetime TB mortality rates, which included deaths from relapse and late complications, were 5% to 15% for patients treated through DOTS and 10% to 30% for patients treated through non-DOTS programs.34,77 Case fatality rates for treatment HIV-negative, smear-negative TB patients were assumed to be half of those for HIV-negative, smear-positive TB patients. For untreated patients with TB, we used CFRs of 70% when they were smear positive and 20% when they were smear negative.30-38

HIV-Positive TB Patients

The survival rate of HIV-positive TB patients varies according to smear status and regimen. It is generally higher for smear-positive than for smear-negative patients,* and it is the lowest with rifampicin-based regimens.†

For smear-positive HIV-positive TB patients treated through DOTS in the WHO African Region we used a CFR of 10% for TB. This choice was based on the assumption that 30% of patients die during treatment, with 25% of these deaths due to TB, and that a further 2.5% will die from recurrent TB or later complications.47,73,74,81,83,88-90 Non-DOTS patients CFRs are higher, at 38%; this assumes a mortality rate of 50% during treatment, with 50% of these deaths due

Table 1. Global Values of Parameters Used in Estimations, With Ranges for Uncertainty Analysis and Sources

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Value</th>
<th>Range</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB incidence rate ratio of HIV-infected to HIV-uninfected individuals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industrialized countries</td>
<td>60</td>
<td>41-77</td>
<td>43-46</td>
</tr>
<tr>
<td>Other countries</td>
<td>6.0</td>
<td>3.5-8.0</td>
<td>10, 38, 39, 47-52</td>
</tr>
<tr>
<td>Proportion of smear-positive TB cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Among HIV-uninfected TB cases</td>
<td>0.45</td>
<td>0.4-0.5</td>
<td>38</td>
</tr>
<tr>
<td>Among HIV-infected TB cases</td>
<td>0.35</td>
<td>0.3-0.4</td>
<td>9, 34, 53</td>
</tr>
<tr>
<td>Ratio of annual risk of MTB infection to incidence rate of smear-positive TB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Countries where risk of infection is constant</td>
<td>50</td>
<td>30-70</td>
<td>54, 55</td>
</tr>
<tr>
<td>Countries where risk of infection is falling</td>
<td>60</td>
<td>40-80</td>
<td>54, 55</td>
</tr>
<tr>
<td>Case fatality rate for untreated TB (deaths from TB)</td>
<td>0.7</td>
<td>0.55-0.75</td>
<td>54, 56, 57</td>
</tr>
<tr>
<td>HIV uninfected, smear positive</td>
<td>0.2</td>
<td>0.1-0.3</td>
<td>56, 58</td>
</tr>
<tr>
<td>HIV uninfected, smear negative</td>
<td>0.81</td>
<td>0.7-0.99</td>
<td>59-62</td>
</tr>
<tr>
<td>HIV infected, smear positive, from TB</td>
<td>0.76</td>
<td>0.63-0.9</td>
<td>59-62</td>
</tr>
<tr>
<td>Ratio of smear-negative to smear-positive case fatality rates for treated cases not infected with HIV</td>
<td>0.5</td>
<td>0.4-0.67</td>
<td>63-66</td>
</tr>
<tr>
<td>Ratio of HIV-infected to HIV-uninfected case fatality rates for treated TB cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smear positive, DOTS</td>
<td>1.0</td>
<td>0.5-1.5</td>
<td>48, 67-69</td>
</tr>
<tr>
<td>Smear positive, non-DOTS</td>
<td>1.27</td>
<td>0.5-3</td>
<td>Assumed: no data</td>
</tr>
<tr>
<td>Smear negative, DOTS</td>
<td>2.0</td>
<td>0.5-3</td>
<td>48, 69</td>
</tr>
<tr>
<td>Smear negative, non-DOTS</td>
<td>3.3</td>
<td>2-10</td>
<td>Assumed: no data</td>
</tr>
<tr>
<td>Duration of illness, untreated TB cases, y</td>
<td>2.0</td>
<td>1.5-2.5</td>
<td>54, 56, 57</td>
</tr>
<tr>
<td>HIV uninfected</td>
<td>0.5</td>
<td>0.25-1</td>
<td>59</td>
</tr>
</tbody>
</table>

Abbreviations: DOTS, the internationally recommended strategy for TB control; HIV, human immunodeficiency virus; MTB, Mycobacterium tuberculosis; TB, tuberculosis.

*Parameters in this table are those used for all countries; parameters with values specific to different countries or groups of countries are available at www.who.int/gtb/tbestimates or from the corresponding author.
†In industrialized countries, where risk of infection is falling steeply, infection prevalence was estimated from surveys instead.
to TB, and a further 12.5% of patients dying after treatment because of late TB complications. These higher CFRs reflect the high risks of noncompliance with treatment, of treatment failure, of adverse drug reactions, and of disease recurrence with unsupervised and non-rifampin-based regimens.21,74-77

Human immunodeficiency virus–positive patients with smear-negative TB are generally more severely immunosuppressed than those with smear-positive TB. Outcomes for them are poor, especially when drug regimens do not contain rifampicin.95,72,74,77,92,93 For smear-negative patients treated through DOTS we used the same CFR of 10% as for smear-positive patients, assuming that the higher mortality rate during treatment is due to a higher risk of other opportunistic infections. We used a CFR of 50% for patients treated outside DOTS programs, assuming a mortality rate of 70% during treatment, with 50% due to TB, and a further 15% due to late TB deaths.80,81,87,95,96 The mortality of untreated HIV-associated TB is extremely high, and we assumed that 90% and 99% of such cases died from TB rather than from HIV infection, and the proportion of those treated might be 5% for smear-positive and 10% for smear-negative patients because more intensive medical care is available, including HAART.32-66

In established market economies, CFRs from TB in treated HIV-positive patients are lower than in sub-Saharan Africa. We assumed them to be 5% for smear-positive and 10% for smear-negative patients because more intensive medical care is available, including HAART.32-66

For nonindustrialized countries outside the WHO African Region, there are insufficient data on survival to base estimates on published reports. Instead, we assumed a constant ratio of HIV-positive to HIV-negative CFRs across regions, and derived HIV-positive CFRs from country-specific HIV-negative CFRs using the ratios shown in Table 1. The overall CFR for each country was the weighted average of each category.

The number of deaths attributable to HIV is the number of extra TB deaths resulting from the higher TB incidence rates and CFRs in patients infected with the virus (equation 9). For each country and region, we calculated the proportion of all TB deaths in people with HIV infection, the proportion of those deaths attributable to HIV, and the proportion of HIV/AIDS deaths that occurred primarily from TB (see below).

Classification of TB Deaths

Patients with TB who are infected with HIV are at high risk of dying from other opportunistic infections during the 6 to 8 months of TB treatment.80,89,96,75,80 They die with TB rather than from TB.95 Unlike the standard WHO cohort analysis of TB patient outcomes, our aim was to estimate deaths from TB.

According to the International Classification of Diseases, 10th Revision (ICD-10), and as reflected in WHO’s World Health Report for 2002,88 deaths from TB in HIV-infected individuals are classified as AIDS deaths. However, because the timing of these deaths is influenced by TB incidence and could be delayed by effective TB treatment, they are included in this analysis and reported separately.

PREVALENCE OF MTB INFECTION AND MTB-HIV COINFECTION

The prevalence rate of MTB infection was derived from the annual risk of TB infection (back-calculated from incidence using equation 3), the rate of decline in the annual risk of TB infection,43 and life expectancy at birth, as previously described.34 Both annual risk of TB infection and life expectancy were taken to be independent of age, and MTB infection was assumed to be lifelong. In eastern and southern African countries, and in Eastern Europe, TB incidence has been increasing for about a decade.75 Although the risk of infection has probably been increasing, too, we did not allow for this increase in calculating the prevalence of infection. This is because the necessary calculations are unduly complex in relation to the quality of data, and the increases may in any case be small.27,64 The prevalence rate of MTB-HIV coinfection was calculated as the product of the prevalence rates of HIV and MTB infection; this calculation underestimates the coinfection rate if the 2 pathogens are associated via shared risk factors.

UNCERTAINTY ANALYSIS

Multivariate uncertainty analyses were used to evaluate the magnitude of the errors surrounding principal estimates of incidence, prevalence, and mortality. Ranges for parameter estimates were obtained from published literature or based on expert opinion (Table 1). When in doubt, we opted for greater uncertainty. Most input variables were assumed to be triangularly distributed, with the apex at the most likely value and lower and upper bounds fixing the width of the base. To determine the uncertainty surrounding point estimates, 1000 simulations were carried out by Latin hypercube sampling (@Risk; Palisade Decision Tools, Newfield, NY). When calculating the uncertainty in estimates for groups of countries (eg, global TB incidence), we distinguished between parameters that varied globally (ie, in the same way across different countries during each simulation) and those that varied for each country independently. Fifth and 95th centiles were used as lower and upper bounds.

RESULTS

ESTIMATES OF REGIONAL IRRS FOR TB

Paired HIV prevalence data from patients with TB and general populations were obtained from previous publications,10,42,43,46-51,98,99 the US Centers for Disease Control and Prevention,35,46 the HIV database kept by the US Census Bureau,102 and UNAIDS.36

Most data were from sub-Saharan Africa, as shown in Figure 2A and B. Data from countries outside Africa being insufficient to permit IRR estimations for each WHO global region, we divided the remaining data into data from nonindustrialized countries outside Africa and data from established market economies. Relevant data are shown in Figure 2C and D. The average for 6 groups of developing countries (3 of which are shown in Figure 2) was an IRR of 5.9, with group averages ranging from 3.5 to 8.0. On this basis, we have used an IRR of 6 for all nonindustrialized countries, with a range of 3.5 to 8 for uncertainty analysis. However, the choice of an IRR of 6 greatly underestimates HIV prevalence for TB patients in industrialized countries.42-44 We derived a better IRR estimate of 60 for the United States from national statistics on adult HIV prevalence and on HIV prevalence in TB patients aged 25 to 44 years (Figure 2D, 1998 data).64,65 This estimate is the approximate midpoint of a lower bound (IRR = 41) obtained by assuming that the 60% of TB patients tested for HIV infection in 1998 included all those who were HIV infected, and an upper bound (IRR = 77) derived from the assumption that those tested were a representative sample of all patients with TB.65 No other industrialized country monitors HIV prevalence in TB patients systematically, but single nationally representative estimates of HIV prevalence in TB patients have
been published for the United Kingdom (3.3%) and Spain (15%). When paired with general population estimates for HIV (0.11% and 0.6%, respectively), these give IRRs of 31 and 29, respectively. In the absence of better information we used an IRR of 60 (range, 41-77), a ratio based on US data, for all industrialized countries.

ESTIMATES OF THE TB BURDEN AND THE IMPACT OF HIV

Here we present an overview of the TB burden that focuses on the impact of HIV. Statistics are given for the world as a whole; for each of the 6 WHO regions (Table 2); and for each of 22 high-burden countries with the largest numbers of cases, which together account for approximately 80% of the world’s new TB cases (Table 3 and Figures 3, 4, and 5). These 22 countries include 5 of the 15 countries with the highest incidence rates per capita (Figure 6). A list of estimates for all countries, together with updates, can be found at www.who.int/gtb/tbestimates, or obtained from the corresponding author.

There were an estimated 8.3 million (7.3-9.2 million) new TB cases in 2000, or 137 (121-151) per 100,000 population; 3.7 million (3.1-4.0 million) were smear positive, ie, 61 (51-66) per 100,000 population. Most new cases were in adults aged 15 to 49 years (5.4 million; 172/100,000). Among WHO regions, the African Region (essentially sub-Saharan Africa) had by far the highest annual incidence rates (290/100,000), while the South-East Asian Region had the largest number of cases (3.0 million). Half the new cases (4.4 million) were in the top 5 countries, all in Asia. Of 15 countries with the highest incidence rates per capita, 13 were in Africa (Figure 6).

The global burden of TB is growing. The total number of new TB cases increased at a rate of 1.8% per year between 1997 and 2000, and incidence rates per capita (all ages) at a rate of 0.4% per year. Case numbers increased much more quickly in the former Soviet Union (6.0% per year) and in the WHO African Region (6.4% per year).

The spatial and temporal variation in TB incidence is strongly associated with the prevalence of HIV infection (Figure 7). In 2000, 11% of all new TB cases in adults (612,000) occurred in persons infected with HIV, and 9% of all new TB cases were directly attributable to HIV. The prevalence rate of HIV infection in new TB cases varied markedly between regions and countries: from 1% in the WHO Western Pacific Region, to 14% in industrialized countries, and 38% in the WHO African Region; from under 1% in Afghanistan, Bangladesh,
The quality of TB treatment and the life expectancy of patients with TB govern the duration of illness, and hence the ratio of prevalence to incidence. We estimate that global TB prevalence was twice the incidence in 2000. The ratio varied by WHO region from 1.4 in the Americas and Europe, to 1.5 in Africa, and 2.4 in South-East Asian Region. This regional variation can be explained by regional differences in HIV prevalence rates and treatment practices, and by the local effect of large countries, such as South Africa (1.2) where high HIV prevalence rates reduces the average life expectancy of TB patients, and India (2.5) where the poor quality of treatment extends the duration of disease. Our assumption of high access to effective treatment leads to a relatively low ratio for the European Region (1.4).

There were 1.84 million (1.59-2.22 million) deaths from TB in 2000, 226,000 attributable to HIV (12%; range, 8%-15%). The 246,000 (range, 167,000-298,000) TB deaths in adults infected with HIV represented 13% of all TB deaths and 11% of 2.3 million adult AIDS deaths, and most of these deaths (203,000) occurred in Africa. Across all countries, the aggregate CFR of HIV-infected TB cases was 40%. The number of people who died from TB was lower in the WHO African Region (482,000) than in South-East Asian Region (727,000), but the annual death rate was far higher (75 vs 47 per 100,000 population).

Tuberculosis death rates in high-burden countries varied dramatically, from 9 per 100,000 population in Brazil to 139 per 100,000 in South Africa. In these 2 countries overall CFRs for TB were 13% and 27%, respectively, and the difference was due largely to the difference in HIV infection rates.

Assuming lifelong MTB infection, and excluding effects on transmission of the recent increases in incidence in Africa and the former Soviet Union, 30% of the world population (1.8 billion people) carried MTB in 2000. Assuming no shared risk factors, the prevalence of MTB-HIV coinfection among adults aged 15 to 49 years was 0.36%, or 11.4 million people. Coinfection prevalence in adults aged 15 to 49 years equaled or exceeded 5% in 8 countries, all on the African continent. The largest numbers of coinfected adults were in South Africa (2.0 million), India (1.7 million), and Nigeria (0.9 million).

This analysis goes beyond previous TB-burden studies in defining the principal trends in TB incidence and in quantifying the impact of HIV. In the WHO African Region (largely sub-Saharan Africa), the impact of HIV is such that TB incidence rates are strongly associated with adult HIV prevalence. We calculated that 31% of adult TB cases were attributable to HIV in the entire African Region in 2000, about the same as determined by more direct methods for some countries.

### Table 2. Summary of TB-HIV Estimates for 2000 by WHO Regions

<table>
<thead>
<tr>
<th>Region</th>
<th>Africa</th>
<th>Americas</th>
<th>Eastern Mediterranean</th>
<th>Europe</th>
<th>South-East Asia</th>
<th>Western Pacific</th>
<th>Global</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population, millions</td>
<td>640</td>
<td>832</td>
<td>485</td>
<td>874</td>
<td>1536</td>
<td>1688</td>
<td>6053</td>
</tr>
<tr>
<td>New cases of TB, all forms</td>
<td>1857</td>
<td>382</td>
<td>587</td>
<td>468</td>
<td>2986</td>
<td>2031</td>
<td>8311</td>
</tr>
<tr>
<td>No. of cases, thousands</td>
<td>290</td>
<td>46</td>
<td>121</td>
<td>54</td>
<td>194</td>
<td>120</td>
<td>137</td>
</tr>
<tr>
<td>Change in incidence rate 1997-2000, %/y</td>
<td>3.9</td>
<td>-4.1</td>
<td>-1.4</td>
<td>2.8</td>
<td>-1.3</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Prevalence of HIV in new adult cases (15-49 years old), %</td>
<td>38</td>
<td>5.9</td>
<td>1.8</td>
<td>2.8</td>
<td>3.2</td>
<td>1.3</td>
<td>11</td>
</tr>
<tr>
<td>Attributable to HIV, thousands</td>
<td>421</td>
<td>12</td>
<td>5.2</td>
<td>8.2</td>
<td>53</td>
<td>13</td>
<td>511</td>
</tr>
<tr>
<td>Attributable to HIV, % of adult cases</td>
<td>31</td>
<td>5.1</td>
<td>1.5</td>
<td>2.6</td>
<td>2.7</td>
<td>1.1</td>
<td>9</td>
</tr>
<tr>
<td>New smear-positive cases of TB</td>
<td>785</td>
<td>169</td>
<td>264</td>
<td>210</td>
<td>1338</td>
<td>913</td>
<td>3679</td>
</tr>
<tr>
<td>No. of cases, thousands</td>
<td>185</td>
<td>27</td>
<td>193</td>
<td>35</td>
<td>209</td>
<td>117</td>
<td>122</td>
</tr>
<tr>
<td>Prevalence rate of SS+ TB, per 100 000 population</td>
<td>7.5</td>
<td>1.0</td>
<td>0.2</td>
<td>0.5</td>
<td>0.3</td>
<td>0.1</td>
<td>1.4</td>
</tr>
<tr>
<td>Proportion of prevalence of SS+ cases infected with HIV, %</td>
<td>31</td>
<td>15</td>
<td>27</td>
<td>14</td>
<td>46</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>Infection prevalence among adults</td>
<td>2.7</td>
<td>0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.3</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Prevalence of MTB infection, %</td>
<td>482</td>
<td>55</td>
<td>135</td>
<td>72</td>
<td>727</td>
<td>368</td>
<td>1839</td>
</tr>
<tr>
<td>Deaths from TB</td>
<td>75</td>
<td>6.6</td>
<td>28</td>
<td>8.3</td>
<td>47</td>
<td>22</td>
<td>30</td>
</tr>
<tr>
<td>Deaths from TB, per 100 000 population</td>
<td>203</td>
<td>3.9</td>
<td>3.0</td>
<td>1.6</td>
<td>29</td>
<td>5.7</td>
<td>246</td>
</tr>
<tr>
<td>Deaths from TB in HIV-positive adults, thousands</td>
<td>12</td>
<td>4.1</td>
<td>11</td>
<td>10</td>
<td>8.1</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>Adult AIDS deaths due to TB, %</td>
<td>39</td>
<td>6.5</td>
<td>2.0</td>
<td>2.1</td>
<td>3.7</td>
<td>1.4</td>
<td>12</td>
</tr>
<tr>
<td>TB deaths attributable to HIV, %</td>
<td>1014</td>
<td>55</td>
<td>135</td>
<td>72</td>
<td>727</td>
<td>368</td>
<td>1839</td>
</tr>
</tbody>
</table>

Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; MTB, Mycobacterium tuberculosis; SS+, smear-positive sputum; TB, tuberculosis; WHO, World Health Organization.
Table 3. Summary of TB-HIV Estimates for 2000 for 22 High-Burden Countries*

<table>
<thead>
<tr>
<th>Country</th>
<th>India</th>
<th>China</th>
<th>Indonesia</th>
<th>Bangladesh</th>
<th>Nigeria</th>
<th>Pakistan</th>
<th>Philippines</th>
<th>South Africa</th>
<th>Russian Federation</th>
<th>Ethiopia</th>
<th>Democratic Republic of Congo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population, millions</td>
<td>1009</td>
<td>1275</td>
<td>212</td>
<td>137</td>
<td>114</td>
<td>141</td>
<td>76</td>
<td>43</td>
<td>145</td>
<td>63</td>
<td>51</td>
</tr>
<tr>
<td>New TB cases, all forms</td>
<td>1816</td>
<td>1437</td>
<td>582</td>
<td>325</td>
<td>261</td>
<td>245</td>
<td>230</td>
<td>220</td>
<td>183</td>
<td>178</td>
<td>150</td>
</tr>
<tr>
<td>Incidence rate per 100 000 population</td>
<td>180</td>
<td>113</td>
<td>274</td>
<td>237</td>
<td>230</td>
<td>173</td>
<td>304</td>
<td>509</td>
<td>126</td>
<td>284</td>
<td>294</td>
</tr>
<tr>
<td>Change in incidence rate 1997-2000, %/y</td>
<td>-1.3</td>
<td>0.0</td>
<td>-1.3</td>
<td>2.4</td>
<td>-1.5</td>
<td>-1.0</td>
<td>8.7</td>
<td>5.9</td>
<td>2.9</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>HIV prevalence in new adult cases (15-49 years old), %</td>
<td>4.0</td>
<td>0.4</td>
<td>0.3</td>
<td>0.1</td>
<td>24</td>
<td>0.6</td>
<td>0.4</td>
<td>60</td>
<td>1.0</td>
<td>42</td>
<td>24</td>
</tr>
<tr>
<td>Attributable to HIV, thousands</td>
<td>41</td>
<td>3.1</td>
<td>0.8</td>
<td>0.2</td>
<td>38</td>
<td>0.7</td>
<td>0.5</td>
<td>80</td>
<td>1.1</td>
<td>45</td>
<td>22</td>
</tr>
<tr>
<td>Attributable to HIV, % of adult cases</td>
<td>3.4</td>
<td>0.4</td>
<td>0.2</td>
<td>0.1</td>
<td>20</td>
<td>0.5</td>
<td>0.3</td>
<td>50</td>
<td>0.9</td>
<td>35</td>
<td>20</td>
</tr>
<tr>
<td>New smear-positive cases of TB</td>
<td>813</td>
<td>646</td>
<td>261</td>
<td>146</td>
<td>113</td>
<td>110</td>
<td>104</td>
<td>90</td>
<td>82</td>
<td>75</td>
<td>65</td>
</tr>
<tr>
<td>Prevalence rates of SS+ TB, per 100 000 population</td>
<td>201</td>
<td>122</td>
<td>325</td>
<td>214</td>
<td>192</td>
<td>213</td>
<td>232</td>
<td>219</td>
<td>88</td>
<td>186</td>
<td>185</td>
</tr>
<tr>
<td>Prevalence of SS+, HIV-positive cases, %</td>
<td>0.6</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>4.5</td>
<td>0.1</td>
<td>0.1</td>
<td>21</td>
<td>0.3</td>
<td>9.5</td>
<td>5.8</td>
</tr>
<tr>
<td>Infection prevalence among adults</td>
<td>46</td>
<td>31</td>
<td>52</td>
<td>46</td>
<td>36</td>
<td>37</td>
<td>52</td>
<td>42</td>
<td>12</td>
<td>27</td>
<td>36</td>
</tr>
<tr>
<td>Prevalence of MTB infection, %</td>
<td>0.3</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>1.8</td>
<td>0.0</td>
<td>0.0</td>
<td>8.3</td>
<td>0.0</td>
<td>2.8</td>
<td>1.8</td>
</tr>
<tr>
<td>Deaths from TB</td>
<td>453</td>
<td>268</td>
<td>146</td>
<td>79</td>
<td>76</td>
<td>65</td>
<td>44</td>
<td>60</td>
<td>33</td>
<td>47</td>
<td>36</td>
</tr>
<tr>
<td>Deaths from TB per 100 000 population</td>
<td>45</td>
<td>21</td>
<td>69</td>
<td>57</td>
<td>67</td>
<td>46</td>
<td>58</td>
<td>139</td>
<td>23</td>
<td>74</td>
<td>70</td>
</tr>
<tr>
<td>Deaths from TB in HIV-positive adults, thousands</td>
<td>24</td>
<td>1.4</td>
<td>0.5</td>
<td>0.1</td>
<td>23</td>
<td>0.5</td>
<td>0.2</td>
<td>38</td>
<td>0.4</td>
<td>21</td>
<td>11</td>
</tr>
<tr>
<td>Adult AIDS deaths due to TB, %</td>
<td>10</td>
<td>8.6</td>
<td>18</td>
<td>13</td>
<td>11</td>
<td>8.0</td>
<td>23</td>
<td>18</td>
<td>35</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>TB deaths attributable to HIV, %</td>
<td>4.8</td>
<td>0.5</td>
<td>0.3</td>
<td>0.1</td>
<td>28</td>
<td>0.7</td>
<td>0.5</td>
<td>59</td>
<td>1.2</td>
<td>41</td>
<td>28</td>
</tr>
</tbody>
</table>

United Republic of Tanzania

<table>
<thead>
<tr>
<th>Country</th>
<th>Vietnam</th>
<th>Kenya</th>
<th>Tanzania</th>
<th>Brazil</th>
<th>Thailand</th>
<th>Myanmar</th>
<th>Zimbabwe</th>
<th>Uganda</th>
<th>Cambodia</th>
<th>Afghanistan</th>
<th>Mozambique</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population, millions</td>
<td>78</td>
<td>31</td>
<td>35</td>
<td>170</td>
<td>63</td>
<td>48</td>
<td>13</td>
<td>23</td>
<td>13</td>
<td>22</td>
<td>18</td>
</tr>
<tr>
<td>New TB cases, all forms</td>
<td>143</td>
<td>138</td>
<td>117</td>
<td>114</td>
<td>86</td>
<td>78</td>
<td>76</td>
<td>75</td>
<td>75</td>
<td>69</td>
<td>48</td>
</tr>
<tr>
<td>Incidence rate, per 100 000 population</td>
<td>183</td>
<td>449</td>
<td>335</td>
<td>67</td>
<td>137</td>
<td>164</td>
<td>604</td>
<td>323</td>
<td>573</td>
<td>319</td>
<td>262</td>
</tr>
<tr>
<td>Change in incidence rate 1997-2000, %/y</td>
<td>-1.0</td>
<td>14</td>
<td>2.8</td>
<td>-3.9</td>
<td>-1.3</td>
<td>-1.3</td>
<td>3.9</td>
<td>0.3</td>
<td>2.0</td>
<td>-1.5</td>
<td>1.0</td>
</tr>
<tr>
<td>HIV prevalence in new adult cases, %</td>
<td>1.4</td>
<td>49</td>
<td>35</td>
<td>3.3</td>
<td>12</td>
<td>11</td>
<td>67</td>
<td>35</td>
<td>20</td>
<td>0.0</td>
<td>48</td>
</tr>
<tr>
<td>Attributable to HIV, thousands</td>
<td>1.0</td>
<td>41</td>
<td>25</td>
<td>1.8</td>
<td>5.1</td>
<td>4.8</td>
<td>31</td>
<td>16</td>
<td>7.7</td>
<td>0.0</td>
<td>14</td>
</tr>
<tr>
<td>Attributable to HIV, % of adult cases</td>
<td>1.2</td>
<td>41</td>
<td>29</td>
<td>2.8</td>
<td>10</td>
<td>9.1</td>
<td>56</td>
<td>29</td>
<td>17</td>
<td>0.0</td>
<td>40</td>
</tr>
<tr>
<td>New smear-positive cases of TB</td>
<td>64</td>
<td>57</td>
<td>50</td>
<td>51</td>
<td>38</td>
<td>35</td>
<td>31</td>
<td>32</td>
<td>34</td>
<td>31</td>
<td>20</td>
</tr>
<tr>
<td>Prevalence rates of SS+ TB, per 100 000 population</td>
<td>96</td>
<td>253</td>
<td>207</td>
<td>46</td>
<td>101</td>
<td>115</td>
<td>282</td>
<td>187</td>
<td>548</td>
<td>310</td>
<td>124</td>
</tr>
<tr>
<td>Prevalence of SS+ HIV-positive cases, %</td>
<td>0.5</td>
<td>13</td>
<td>8.4</td>
<td>0.7</td>
<td>2.5</td>
<td>2.5</td>
<td>21</td>
<td>9.1</td>
<td>3.5</td>
<td>0.0</td>
<td>15</td>
</tr>
<tr>
<td>Infection prevalence among adults</td>
<td>44</td>
<td>23</td>
<td>33</td>
<td>19</td>
<td>43</td>
<td>41</td>
<td>20</td>
<td>15</td>
<td>76</td>
<td>56</td>
<td>25</td>
</tr>
<tr>
<td>Prevalence of MTB infection, %</td>
<td>0.1</td>
<td>3.2</td>
<td>2.7</td>
<td>0.1</td>
<td>0.9</td>
<td>0.8</td>
<td>5.0</td>
<td>1.3</td>
<td>3.1</td>
<td>0.0</td>
<td>3.3</td>
</tr>
<tr>
<td>Prevalence of MTB-HIV coinfection, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths from TB</td>
<td>19</td>
<td>35</td>
<td>27</td>
<td>15</td>
<td>13</td>
<td>19</td>
<td>16</td>
<td>19</td>
<td>16</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>Deaths from TB per 100 000 population</td>
<td>24</td>
<td>115</td>
<td>77</td>
<td>8.8</td>
<td>21</td>
<td>40</td>
<td>130</td>
<td>82</td>
<td>121</td>
<td>92</td>
<td>70</td>
</tr>
<tr>
<td>Deaths from TB in HIV-positive adults, thousands</td>
<td>0.3</td>
<td>19</td>
<td>11</td>
<td>0.6</td>
<td>1.8</td>
<td>2.6</td>
<td>9.7</td>
<td>7.9</td>
<td>3.6</td>
<td>0.0</td>
<td>6.8</td>
</tr>
<tr>
<td>Adult AIDS deaths due to TB, %</td>
<td>12</td>
<td>11</td>
<td>12</td>
<td>3.2</td>
<td>3.0</td>
<td>6.2</td>
<td>7.5</td>
<td>8.1</td>
<td>30</td>
<td>0.0</td>
<td>9.8</td>
</tr>
<tr>
<td>TB deaths attributable to HIV, %</td>
<td>1.6</td>
<td>48</td>
<td>36</td>
<td>3.4</td>
<td>12</td>
<td>13</td>
<td>53</td>
<td>38</td>
<td>21</td>
<td>0.0</td>
<td>49</td>
</tr>
</tbody>
</table>

*See footnote to Table 2 for explanation of abbreviations.
In the same region, HIV-infected cases were responsible for an estimated 7% of all TB transmission. The spread of HIV across sub-Saharan Africa is primarily responsible for driving the number of TB cases upwards at 6% per year, though we expect growth to slow as HIV epidemics peak—and there are signs that this is beginning to happen. Some countries with high incidence rates have small populations, and are therefore not included among the rankings in Table 3, which are based on numbers of cases. However, TB is clearly a major burden for these countries, many of which are in Africa.

Our results indicate that the HIV epidemic is exacerbating TB transmission, although on a case-by-case basis disproportionately few infections come from HIV-infected patients. This is because TB patients with HIV are less likely to be smear-positive than patients without HIV, and the duration of infectiousness is relatively brief in them because they have a relatively rapid progression of disease. Our results in this respect are qualitatively consistent with those of surveys in Africa. These surveys show either no increase, or relatively small increases, in the annual risk of TB infection in children, despite a severalfold increase in national TB incidence rates over the same period.

Inevitably, the burden of MTB-HIV coinfection is increasing as HIV spreads. Coinfection prevalence rates have reached startlingly high levels in African countries such as Botswana, Zimbabwe, and South Africa. And although the proportion of people coinfected in Asian countries is typically of a lower order of magnitude, the ab-

Figure 3. Estimated numbers of tuberculosis cases by country in 2000.

Figure 4. Estimated numbers of human immunodeficiency virus–infected tuberculosis cases per 100 000 population (all ages) by country in 2000.
solute number of coinfected people in Asia exceeds 2 million. Without interventions to treat HIV-induced immunosuppression, latent TB infection, or both, a high proportion of these coinfected individuals can be expected to develop active TB. The estimates in this article suggest a lifetime risk of 30% to 40% for coinfected persons in Africa (assuming a mean survival time of 6 to 10 years after HIV infection). In this context, Brazil is still the only country with a large number of coinfected people (100,000), a policy of universal access to HAART, and therefore the potential to reduce the risk of HIV-related TB.

Even in regions with low TB incidence, HIV has had a marked impact. For example, HIV prevalence rates in patients with TB are high in the United States, as are IRRs, and we estimate that 26% of TB cases were attributable to HIV. This is well above the attributable proportions calculated for Latin American and Asian countries that have higher prevalence rates of MTB infection and equal or higher HIV prevalence rates. There are at least 2 possible explanations for this. The first is that both HIV and MTB infections tend to be concentrated within the same subpopulations in countries where neither infection is generalized. In Spain, for example, both HIV and MTB infection and disease are strongly associated with intravenous drug use, and coinfection rates within this behavioral group are extremely high. In the United States, rates of both HIV and TB infections are disproportionately high in certain ethnic groups. Non-random associations between HIV and MTB infections increase the likelihood of coinfection, further increasing the already high incidence rate of TB in HIV-infected individuals. The second possibility is that, unlike MTB-HIV-coinfected individuals, a relatively high proportion of HIV-uninfected MTB-infected people in low-incidence, industrialized countries are in the older age groups, and acquired their infections many years ago, when TB transmission rates were higher than they are now. Most of these people develop TB at the low reactivation rate characteristic of long-standing infections, thereby increasing the difference between themselves and TB-HIV-coinfected individuals.

Although the most alarming TB-HIV statistics are generally connected with Africa, the link between HIV and drug resistance could have greater epidemiological significance elsewhere. Multidrug-resistant TB (MDR-TB) has remained uncommon in most parts of Asia and

Figure 5. Proportions of adult tuberculosis cases attributable to human immunodeficiency virus by country in 2000.

Figure 6. Fifteen countries with the highest estimated tuberculosis (TB) incidence rates per capita (all ages) and corresponding incidence rates of human immunodeficiency virus (HIV)–infected TB. Numbers above the bars are percentages of Mycobacterium tuberculosis–HIV coinfected.
Eastern Europe where drug resistance is more firmly established, the number of persons infected with both HIV and MDR-TB is likely to increase.20,21 As HIV generates a greater number of MDR-TB cases, the frequency of drug resistance among new cases may increase. At the institutional level, HIV has been associated with epidemic MDR-TB transmission in a number of countries.20-21 On a far larger scale, India has 1.7 million people coinfected with MTB and HIV, and a multidrug resistance rate of 2% to 5% among previously untreated individuals with TB.109

Even without the complication of drug resistance, high death rates are reported for patients treated for HIV-associated TB.47,48,62,63,67,68,74,76-80 Deaths rates may be even higher, and it is possible that fewer than half the fatal TB cases are diagnosed before death.22-26 The reality is that the proportion of TB deaths attributable to HIV (12%) is higher than the proportion of new TB cases (11%), and we estimate the overall CFR for HIV-related TB (including undiagnosed cases) to be over 50% in many developing countries.

These calculations also imply that the contribution of TB to AIDS deaths is substantial: 11% of AIDS deaths are deaths primarily from TB. Even higher proportions, between 20% and 50%, have been found in autopsy studies, but these were based in high-incidence urban settings and may be unrepresentative.22-24

We stress that the calculations in this analysis, as in all other similar analyses, are subject to error. Our country and regional estimates were derived from a mixture of research and surveillance data and expert opinion, and the quality of the information varies from very high to very low. For this reason, we explored the variation around estimates using multivariate uncertainty analyses that aim to overstate rather than understate errors. Point estimates are commonly used to express the magnitude of the TB problem and its link with HIV, and the present article provides more statistics of this kind. However, it is crucial to appreciate that, for example, while the upper estimate of global TB incidence is roughly 25% greater than the lower estimate, for certain high-incidence countries lower and upper estimates differ by a factor of 2. Among countries ranked by incidence, Côte d’Ivoire, in 24th place, has only 5% more cases than Cameroon, in 30th place. Such rankings must therefore be used with great caution.

We were not able to carry out a full appraisal of uncertainty because some unknowns lie beyond the scope of formal, multivariate analyses. Thus, in using a single IRR value to estimate HIV prevalence in TB cases in developing countries, we did not account for the fact that IRR is likely to increase as an HIV epidemic matures in any country, and a higher proportion of HIV-infected people becomes immunosuppressed.113 Moreover, our choice of dichotomous IRRs, set at 6 or 60, reflects the paucity of data in industrialized countries and elsewhere. There is weak (statistically nonsignificant) evidence for an IRR greater than 6 in some middle-income countries. From 22 observations in Latin America we obtained an IRR average of approximately 10, but with enormous variation (range, 0.6-112) between sites. We may therefore have underestimated the proportion of cases and deaths attributable to HIV in these countries, but the extent of any bias is presently unclear.

The IRR for TB has been measured directly in a number of cohort studies.6,100,118-119 In Africa estimates vary from 4.9 to 26, although most are of limited precision because of a small number of HIV-negative cases.100,113,117-119 Estimates in the present study are similar to estimates found in 2 large cohort studies: a relative risk of 7.1 in a population-based study in Malawi,100 and an IRR of 4.9 among South African gold miners.111 Outside Africa, IRRs of 10 and 14 were observed among American intravenous drug users with MTB infection111 and Brazilian female prisoners,110 respectively. However, it was previously noted that the population-based IRR would have to be many times higher than these estimates to account for the impact of HIV on TB in the United States.120

Most of the recent successes in TB control have been in countries with low rates of HIV infection such as China, Peru, and Vietnam.37,121,122 Yet TB in HIV-infected patients is both treatable and preventable (Table 4).1 Achieving TB control in populations with high HIV prevalence rates requires more than wide-scale implementation of the DOTS strategy.128 There is urgent need to implement a strategy of extended

Table 4. Interventions to Reduce TB Morbidity and Mortality Associated With HIV

<table>
<thead>
<tr>
<th>Intervention</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reducing risk of HIV infection</td>
<td>20-21, 25</td>
</tr>
<tr>
<td>Condom use and STD control</td>
<td></td>
</tr>
<tr>
<td>Availability of voluntary counseling and testing</td>
<td>126</td>
</tr>
<tr>
<td>Safe needles for injecting drugs</td>
<td>124</td>
</tr>
<tr>
<td>Reducing TB transmission events</td>
<td></td>
</tr>
<tr>
<td>Control of nosocomial and community TB transmission</td>
<td>127</td>
</tr>
<tr>
<td>Reducing risk of TB among persons already infected with HIV</td>
<td></td>
</tr>
<tr>
<td>Treatment of latent TB infection</td>
<td></td>
</tr>
<tr>
<td>Treatment of multidrug-resistant MTB</td>
<td>125, 105, 106</td>
</tr>
<tr>
<td>Reducing the case fatality rate of HIV-associated TB</td>
<td></td>
</tr>
<tr>
<td>Prompt diagnosis</td>
<td>45</td>
</tr>
<tr>
<td>Use of rifampicin-containing short-course regimen</td>
<td>94</td>
</tr>
<tr>
<td>Concurrent administration of prophyactic cotrimoxazole</td>
<td>82</td>
</tr>
<tr>
<td>Treatment of immunosuppression with antiretroviral drugs</td>
<td>82, 105, 106</td>
</tr>
</tbody>
</table>

Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis; STD, sexually transmitted diseases.
scope combining intensified TB case finding and treatment, HIV prevention, and the identification and treatment of latent TB in coinfected individuals. Controlling HIV-related TB will require a massive global effort. The estimates in this article provide a measure of this challenge, and suggest ways to monitor the impact of efforts to control HIV-related TB.

Accepted for publication July 11, 2002. Drs. Corbett and Watt contributed equally to this work.

This study was supported by a grant to WHO from the US Agency for International Development (USAID). Dr Corbett is funded by the Wellcome Trust.

The designations used and the presentation of material in Figures 3, 4, and 5 do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city, or area or of any of its authorities, or concerning the delimitation of its frontiers or boundaries.

For their expert advice on TB and HIV in specific countries and worldwide, we thank Léopold Blanc, Pierpaolo de Colombani, Martin Grin-afon, Rodolfo Rodriguez Cruz, Mercedes Diez, Bruno Hubert, Fabio Luelmo, Marisa Moore, Eva Nathan-son, Holger Sawert, Arnaud Tré-bucq, John Watson, and Richard Zaleski.

Input data and TB estimates for all countries are available at www.who.int/gtb/thestimates or from the corresponding author.

Corresponding author and re-prints: Christopher Dye, DPhil, Communicable Diseases, World Health Or-ganization, CH-1211 Geneva 27, Switzerland (e-mail: dyec@who.int).

REFERENCES

1. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV-infec-
2. Daley CL, Small PM, Schecter GF, et al. An out-
break of tuberculosis with accelerated prog-
ression among persons infected with the human im-
3. Shafer RW, Singh SP, Larkin C, Small PM. Ex-
ogenous reinfection with multidrug-resistant My-
cobacterium tuberculosis in an immunocompe-
4. Sutherland I. Recent studies in the epidemi-
5. Vynnycky E, Fine PE. The natural history of tu-
berculosis: the implications of age-dependent risks of disease and the role of reinfection. Epi-
6. Selwyn PA, Hartel D, Lewis VA, et al. A prospec-
tive study of the risk of tuberculosis among in-
travenous drug users with human immunode-
ficiency virus infection. N Engl J Med. 1989;320:
545-550.
7. Girard E, Raviglione MC, Antonucci G, Godfrey-
Faussett P, Ippolito G. Impact of the HIV epi-
demic on the spread of other diseases: the case of tuberculosis. AIDS. 2000;14(supp1 3):S47-
S56.
8. Cantwell MF, Binkin NJ. Tuberculous in sub-
Saharan Africa: a regional assessment of the im-
9. Raviglione MC, Harries AD, Misika R, Wilkin-
don D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS. 1997;11(supp1 B):S115-
S123.
450.
11. Churchyard GJ, Kleinschmidt I, Corbett EL, Mul-
der D, De Cock KM. Mycobacterial disease in South African gold miners in the era of HIV in-
fec tion. Int J Tuberc Lung Dis. 1999;3:791-
798.
12. Kenyon TA, Mvawaseka MJ, Huebner R, Rumi-
sha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculo-
sis and human immunodeficiency virus co-
13. Thongcharoen P, Vitayasai P, Vitayasai V, Sup-
aratpinyo K, Tansuphaswadikul S. Opportunist-
tic infections in AIDS/HIV infected patients in
15. Grant AD, Djomand G, De Cock KM. Natural his-
spective study of community-acquired blood-
17. Archibald LK, den Dulk MO, Pallangyo KJ, Rel-
ler LB. Fatal Mycobacterium tuberculosis blood-
18. Archibald LK, McDonald LC, Rheumaptinkantik S, et al. Fever and human immunodeficiency vi-
rus infection as sentinel for emerging myco-
bacterial and fungal bloodstream infections in hos-
19. McDonald LC, Archibald LK, Rheumaptinkantik S, et al. Unrecognised Mycobacterium tuber-
culosi bacteriaemia among hospital inpatients in less developed countries. Lancet. 1999;354:
1159-1163.
20. Archibald LK, McDonald LC, Nevanjanayo O, et al. A hospital-based prevalence survey of blood-
stream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Ac-
quire Immune Defic Syndr Hum Retrovirol. 2000;
18:1414-1420.
cal and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS. 1993;7:1241-
1245.
24. Lucas SB, Hounoua A, Peacock C, et al. The mor-
topsy findings in 70 AIDS patients who died in a department of pneumology in Ivory Coast: im-
55:252-254.
26. Rana FS, Hawkwn MP, Mnaachari C, et al. Au-
topsy study of HIV-1-positive and HIV-1-
29. Moss AR, Alland D, Teltzak E, et al. A city-wide outbreak of a multiple-drug-resistant strain of My-
cobacterium tuberculosis in New York. Int J Tu-
30. Moro ML, Gora A, Errante I, et al. For the Italian Mul-
tidrug-Resistant Tuberculosis Outbreak Study
Group. An outbreak of multidrug-resistant tuber-
culosis involving HIV-infected patients of two hos-
inital in Milan, Italy. AIDS. 1998;12:1095-1102.
ocomial spread of human immunodeficiency virus-
related multidrug-resistant tuberculosis in Bue-
32. Goble M, Ismaen MD, Madsen LA. Treatment of 171 patients with pulmonary tuberculosis resis-
34. Dye C, Scheele S, Dolin P, Palttamas R, Ravi-
glione MC. Global burden of tuberculosis: esti-
35. Coovadia HM, Neena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculo-
37. World Health Organization. Global Tuberculo-
sis Control. Geneva, Switzerland: World Health
bacterial infection and the risk of developing in-
50:117-119.
56. Hilleboe HE. Post-sanatorium tuberculosis sur-
vival rates in Minnesota. Public Health Rep: 1941;
56:895-907.
57. National Tuberculosis Institute Bangalore. Tu-
59. Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected per-
llosis in patients with advanced human immu-
324:289-296.
61. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treat-
ment and all-cause mortality in patients with tu-
62. Palmieri F, Pellicelli AM, Girardi E, et al. Neg-
tive predictors of survival in HIV-infected pa-
tients with culture-confirmed pulmonary tubercu-
63. Shafer RW, Bloch AB, Larkin C, et al. Predictors of survival in HIV-infected tuberculosis pa-
64. Whalen C, Horsburgh-CR Jr, Hom D, Lahart C, Simberkoff M, Elner J. Site of disease and opportunistic infection predict survival in HIV-
associated tuberculosis. AIDS. 1997;11:455-
460.
munodeficiency virus serostatus in Zomba Hos-
92:343-347.
66. Ya Diul M, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence popula-
tions in sub-Saharan Africa. AIDS. 2001;15:143-
152.
67. Ackah CA, Coulibaly D, Digbeu H, et al. Re-
sponse to treatment, mortality, and CD4 lym-
phocyte counts in HIV-infected persons with tu-
berculosis in Abidjan, Côte d’Ivoire. Lancet. 1995;
349:607-610.
68. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-
69. Churchyard GJ, Corbett EL, Kleinschmidt I, Mur-
ray J, Smid J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-
infected and non-HIV-infected South African gold min-
70. Styblo K. Overview and epidemiologic assess-
ment of the current global tuberculosis situa-
71. Grzybowski S, Enarson DA. The fate of pulmo-
nary tuberculosis under various treatment pro-
grames. Bull Int Union Tuberc. 1978;53:70-
75.
HIV-1 seropositive patients treated for tubercu-
73. Johnson JL, Okwera A, Uj M, et al. Risk fac-
tors for relapse in human immunodeficiency vi-
rus type 1 infected adults with pulmonary tu-
75. Brindle RJ, Nunn PP, Batchelor BI, et al. In-
76. Okwera A, Whalen C, Byevoso F, et al. Ran-
domised trial of thiacetazone and rifampcin-
containing regimens for pulmonary tuberculo-
sis in HIV-infected Ugandans. Lancet 1994;344:
1323-1328.
77. Elliott AM, Hamlainvi B, Hayes RJ, et al. The im-
 pact of human immunodeficiency virus on mor-
tality of patients treated for tuberculosis in a co-
78. Kasiim S, Sasan MM, Ackah A, et al. Two-
year follow-up of persons with HIV-1- and HIV-
munodeficiency virus infection on the outcome of treatment and survival of tuberculosis pa-
80. Wiktor SZ, Sasan MM, Grant AD, et al. Effi-
cacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1infected patients with tuberculosis in Abidi-
81. Connolly C, Reid A, Davies G, Sturw M, McAdam KP, Wilkinson D. Relapse and morta-
ality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS. 1999;13:1543-1547.
82. Girardi E, Palmeieri F, Cingolani A, et al. Chang-
ing clinical presentation and survival in HIV-
associated tuberculosis after highly active anti-
83. Conti S, Masocco M, Pezzotti P, et al. Differen-
tial impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-
85. Mallory KM, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. Impact of HIV infection on rates of recurrence after treatment for tubercu-
tality rates in tuberculosis patients in Zomba Hos-
88. Sonnengberg P, Murray J, Glynn JR, Shearer S,